Leqvio FDA Approval
The price of Leqvio® reflects its value as an innovative, LDL-lowering
treatment that uniquely addresses key unmet needs in ASCVD
Clinical benefits of Leqvio®
✓ Efficacy
✓ Safety
Non-clinical benefits of LeqvioⓇ
Adherence
Access
Leqvio provides
effective and
sustained LDL-C
reduction up to 52%
vs. placebo 1,2
LeqvioⓇ offers a
demonstrated safety
profile, generally well
tolerated across
different patient
populations
Effective and
sustained LDL-C
reduction with
two HCP-
administered doses
per year³
Medical benefit
coverage for majority
of patients at launch
Affordability
2/3 of patients pay
as little as $0 co-pay
at launch
$3,250
x2
Price per dose (WAC)
Doses per year³
$6,500 Annualized price
☐
■ Value-based
Cost-effective
LDL-C - Low Density Lipoprotein Choletsterol ASCVD - Atherosclerotic Cardiovascular Disease HCP Healthcare Professional WAC Wholesale Acquisition Cost 1. Khvorova A, et al. N Engl J Med. 2017;376:4-7 2. Fitzgerald K,
et al. N Engl J Med. 2017;376:41-51. 3. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin
22 LeqvioⓇ FDA Approval | December 23, 2021 | Novartis Investor Presentation
U NOVARTIS | Reimagining MedicineView entire presentation